“We think this is a very big opportunity for us, if we can roll out this dose as an annual high-efficiency respiratory booster,” CEO Stefan Bancel said during a presentation to brief investors on the drugs in development. “We believe Moderna can be the first to market this important new opportunity,” he added. The company is conducting clinical trials of the RSV vaccine in the elderly.
The drug company already had several candidate influenza vaccines in development. The new vaccine combines the influenza vaccine with the Corona 19 Covid vaccine.
early stage study
For its part, Novavax said on Wednesday that it had also started an early-stage study to test its combined influenza and Covid vaccine.
Moderna also provided updates on its experience testing an approved COVID vaccine for children aged 6 months to under 12 years old.
Moderna’s vaccine, which received emergency clearance for people 18 and older in the United States in December, is currently under FDA review for use by teens and has yet to receive official approval.
A competing vaccine from Pfizer Inc and German partner BioNTech for ages 12 to 15 was officially licensed earlier this year by the US Food and Drug Administration.